Sclerosing Bone Dysplasias and Associated Genetic Disorders

Sclerosing bone dysplasias are a heterogeneous group of rare skeletal disorders characterised by abnormally increased bone density and altered microarchitecture. These conditions range from localised forms, such as melorheostosis, to generalised syndromes including osteopetrosis and osteopoikilosis. Clinically, patients may present with limb deformities, chronic pain, nerve entrapment and recurrent fractures. Pathophysiologically, many of these disorders arise from dysregulation of osteoclast or osteoblast activity owing to germline or somatic mutations in genes governing bone remodelling. Key molecular pathways implicated include the RANK–RANKL axis, the chloride channel CLCN7, proton pump enzyme TCIRG1, TGFβ/BMP signalling modulated by LEMD3, and the RAS–MAPK cascade. Advances in genetic sequencing have revealed both hereditary and mosaic mutations, offering new insights into disease mechanisms. Imaging remains central to diagnosis, with characteristic radiographic patterns such as the “dripping candle wax” of melorheostosis. Management is largely supportive, ranging from bisphosphonate therapy to surgical correction of deformity, while emerging targeted therapies aim to modulate specific signalling aberrations. Understanding these rare disorders has broad relevance, informing normal bone biology and the development of novel orthopaedic interventions.

Research from Nature Portfolio

Recent studies have demonstrated that somatic activating mutations in the MAP2K1 gene underlie many cases of melorheostosis. High-depth sequencing of affected bone tissue revealed mosaic MAP2K1 variants clustering within the MEK1 regulatory domain. Functional assays in patient-derived osteoblasts showed enhanced ERK1/2 phosphorylation, increased cell proliferation and impaired mineralisation in response to BMP2. These findings establish a direct link between aberrant MAPK pathway activation and the distinctive hyperostotic lesions, and they highlight MEK inhibition as a rational therapeutic approach for this hitherto untreatable disorder.

Sclerosing Bone Dysplasias and Associated Genetic Disorders publication trend

The graph below shows the total number of articles in sclerosing bone dysplasias and associated genetic disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Sclerosing bone dysplasia: A disorder characterised by abnormal hardening or increased density of bone tissue.

Mosaicism: The presence of two or more genetically distinct cell populations within one individual, arising post-zygotically.

Osteoclast: A multinucleated cell responsible for bone resorption and remodelling.

Osteoblast: A mononuclear cell tasked with bone matrix synthesis and mineralisation.

MEK1 (MAP2K1): A kinase in the RAS–MAPK pathway that phosphorylates and activates ERK1/2.

Germline mutation: A hereditary alteration present in the egg or sperm that can be transmitted to offspring.

References

1. Somatic activating mutations in MAP2K1 cause melorheostosis. Nature Communications (2018).
2. Melorheostosis and Osteopoikilosis: A Review of Clinical Features and Pathogenesis. Calcified Tissue International (2019).
3. Melorheostosis: A Review of the Literature and a Case Report. Medicina (2023).